Skip to main content
SpringerLink
Log in
Book cover

Medical Therapy in Urology pp 73–87Cite as

LUTS/Benign Prostatic Hyperplasia

  • Chapter
  • First Online:

  • 715 Accesses

Abstract

As the terminology in Benign Prostatic Hyperplasia (BPH) can be very confusing, there has been a recent drive to correctly define the terms in this field of urology (Table 6.1). For the purposes of this chapter, we will refer to lower urinary tract symptoms (LUTS) resulting from benign prostate enlargement (BPE) suggestive of BPH, as LUTS/BPH. Importantly, the previously used term “prostatism” is outdated, nonspecific, and should not be used for such patients any more.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Barry NJ, Fowler FJ, O’ Leary MP et al (1992) The American urological association symptom index for benign prostatic hyperplasia. J Urol 148:1549–1557

    CAS  PubMed  Google Scholar 

  2. McConnell JD, Roehborn CG, Bautista OM (2003) The long term effects of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398

    Article  CAS  PubMed  Google Scholar 

  3. Kirby RS, Pool JL (1997) Alpha adrenoreceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol 80:521–532

    CAS  PubMed  Google Scholar 

  4. Van Kerredroeck P, Jardin A, Laval KU, van Caugh P, ALFORTI Study Group (2000) Efficacy and safety of a new prolonged release formulation of the alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 37:306–313

    Article  Google Scholar 

  5. JE Edwards, Moore RA (2202) Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 14

    Google Scholar 

  6. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. finasteride long-term efficacy and safety study group. N Eng J Med 338:557–563

    Article  CAS  Google Scholar 

  7. Thompson IM, Phyllis J, Goodman MS, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. NEJM 349(3):213–222

    Article  Google Scholar 

  8. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TLJ, Roehrborn C (2004) Efficacy and safety of long-term treatment with the dual 5á-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46:488–495

    Article  CAS  PubMed  Google Scholar 

  9. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G et al (1996) The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med 335(8):533–539

    Article  CAS  PubMed  Google Scholar 

  10. Kirby RS, Altwein JE, Bartsch G et al (1999) Results of the PREDICT (prospective european doxazosin and combination therapy) trial. J Urol 148:1467–1474

    Google Scholar 

  11. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296:2319

    Article  CAS  PubMed  Google Scholar 

  12. Rovner Eric S, Kreder K, Sussman David O, Kaplan Steven A, Carlsson M, Bavendam T, Zhonghong G (2008) Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 180(3):1034–1041

    Article  CAS  PubMed  Google Scholar 

  13. Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R (2004) Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 93(7):985–990

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Morriston Hospital ABM University Hospitals NHS Trust, Swansea, UK

    Katie Moore

Authors
  1. Katie Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jay Khastgir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katie Moore .

Editor information

Editors and Affiliations

  1. Urology Department, St. Bartholomew¿s Hospital, King George V Bldg., London, EC1A 7BE, United Kingdom

    I. S. Shergill

  2. 24 St Nicholas Place, Loughton, IG10 1BF, United Kingdom

    Manit Arya

  3. Dept. Urology, King's College Hospital, Denmark Hill, London, SE5 9RS, United Kingdom

    Philippe R. Grange

  4. Medical School, University College London, Riding House St. 48, London, W1W 7EY, United Kingdom

    A.R. Mundy

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag London

About this chapter

Cite this chapter

Moore, K., Khastgir, J. (2010). LUTS/Benign Prostatic Hyperplasia. In: Shergill, I., Arya, M., Grange, P., Mundy, A. (eds) Medical Therapy in Urology. Springer, London. https://doi.org/10.1007/978-1-84882-704-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-84882-704-2_6

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84882-703-5

  • Online ISBN: 978-1-84882-704-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation